|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schall TJ, Bacon K, Toy KJ and Goeddel DV:
Selective attraction of monocytes and T lymphocytes of the memory
phenotype by cytokine RANTES. Nature. 347:669–671. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roth SJ, Carr MW and Springer TA: C-C
chemokines, but not the C-X-C chemokines interleukin-8 and
interferon-gamma inducible protein-10, stimulate transendothelial
chemotaxis of T lymphocytes. Eur J Immunol. 25:3482–3488. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de la Rosa G, Longo N, Rodríguez-Fernández
JL, Puig-Kroger A, Pineda A, Corbí AL and Sánchez-Mateos P:
Migration of human blood dendritic cells across endothelial cell
monolayers: Adhesion molecules and chemokines involved in
subset-specific transmigration. J Leukoc Biol. 73:639–649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taub DD, Sayers TJ, Carter CR and Ortaldo
JR: Alpha and beta chemokines induce NK cell migration and enhance
NK-mediated cytolysis. J Immunol. 155:3877–3888. 1995.PubMed/NCBI
|
|
7
|
Kameyoshi Y, Dörschner A, Mallet AI,
Christophers E and Schröder JM: Cytokine RANTES released by
thrombin-stimulated platelets is a potent attractant for human
eosinophils. J Exp Med. 176:587–592. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conti P, Pang X, Boucher W, Letourneau R,
Reale M, Barbacane RC, Thibault J and Theoharides TC: RANTES is a
pro-inflammatory chemokine and chemoattracts basophil cells to
extravascular sites. J Pathol. 183:352–358. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ben-Baruch A: Inflammation-associated
immune suppression in cancer: The roles played by cytokines,
chemokines and additional mediators. Semin Cancer Biol. 16:38–52.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moran CJ, Arenberg DA, Huang CC, Giordano
TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash
S and Beer DG: RANTES expression is a predictor of survival in
stage I lung adenocarcinoma. Clin Cancer Res. 8:3803–3812.
2002.PubMed/NCBI
|
|
11
|
Vaday GG, Peehl DM, Kadam PA and Lawrence
DM: Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Prostate. 66:124–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki
Y and Abe A: Correlation of tissue and plasma RANTES levels with
disease course in patients with breast or cervical cancer. Clin
Cancer Res. 7:285–289. 2001.PubMed/NCBI
|
|
13
|
Kim HK, Song KS, Park YS, Kang YH, Lee YJ,
Lee KR, Kim HK, Ryu KW, Bae JM and Kim S: Elevated levels of
circulating platelet microparticles, VEGF, IL-6 and RANTES in
patients with gastric cancer: Possible role of a metastasis
predictor. Eur J Cancer. 39:184–191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sugasawa H, Ichikura T, Kinoshita M, Ono
S, Majima T, Tsujimoto H, Chochi K, Hiroi S, Takayama E, Saitoh D,
et al: Gastric cancer cells exploit CD4+ cell-derived
CCL5 for their growth and prevention of CD8+
cell-involved tumor elimination. Int J Cancer. 122:2535–2541. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duell EJ, Casella DP, Burk RD, Kelsey KT
and Holly EA: Inflammation, genetic polymorphisms in
proinflammatory genes TNF-A, RANTES, and CCR5, and risk of
pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev.
15:726–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karnoub AE, Dash AB, Vo AP, Sullivan A,
Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg
RA: Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arndt CA, Rose PS, Folpe AL and Laack NN:
Common musculoskeletal tumors of childhood and adolescence. Mayo
Clin Proc. 87:475–487. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aldinucci D and Colombatti A: The
inflammatory chemokine CCL5 and cancer progression. Mediators
Inflamm. 2014:2923762014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang CY, Fong YC, Lee CY, Chen MY, Tsai
HC, Hsu HC and Tang CH: CCL5 increases lung cancer migration via
PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 77:794–803.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borsig L, Wolf MJ, Roblek M, Lorentzen A
and Heikenwalder M: Inflammatory chemokines and metastasis-tracing
the accessory. Oncogene. 33:3217–3224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang SW, Liu SC, Sun HL, Huang TY, Chan
CH, Yang CY, Yeh HI, Huang YL, Chou WY, Lin YM and Tang CH:
CCL5/CCR5 axis induces vascular endothelial growth factor-mediated
tumor angiogenesis in human osteosarcoma microenvironment.
Carcinogenesis. 36:104–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang SW, Wu HH, Liu SC, Wang PC, Ou WC,
Chou WY, Shen YS and Tang CH: CCL5 and CCR5 interaction promotes
cell motility in human osteosarcoma. PLoS One. 7:e351012012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stormes KA, Lemken CA, Lepre JV, Marinucci
MN and Kurt RA: Inhibition of metastasis by inhibition of
tumor-derived CCL5. Breast Cancer Res Treat. 89:209–212. 2005.
View Article : Google Scholar : PubMed/NCBI
|
